Exploring the relationship between melanopsin gene variants, sleep, and markers of brain health

The authors acknowledge the participants of the Australian Imaging, Biomarker and Lifestyle (AIBL) Flagship Study of Ageing (AIBL Study) and their families and thank them for their ongoing support of research into Alzheimer's disease. The AIBL Study () is a consortium between Austin Health, CSIRO, Edith Cowan University, the Florey Institute (The University of Melbourne), and the National Ageing Research Institute (Australia). Finally, we thank all AIBL investigators, not listed as authors, who contributed to the design and implementation of the resource but did not actively contribute data to, or participate in the development, analysis, interpretation, or writing of this current study. The AIBL Study has received partial financial support from the Alzheimer's Association (USA), the Alzheimer's Drug Discovery Foundation, an Anonymous Foundation, the Science and Industry Endowment Fund, the Dementia Collaborative Research Centres, the Victorian Government's Operational Infrastructure Support program, the Australian Alzheimer's Research Foundation (now Alzheimer's Research Australia), the National Health and Medical Research Council (NHMRC), and the Yulgilbar Foundation. Numerous commercial interactions have supported data collection and analyses. This includes genetic data utilized in this study, which has also been supported by grants awarded to S.M.L. by the NHMRC (GNT1161706, GNT2001320). In-kind support has also been provided by Sir Charles Gairdner Hospital, Cogstate Ltd., Hollywood Private Hospital, The University of Melbourne, and St Vincent's Hospital. S.R.R.S. is supported by an NHMRC Investigator Grant (GNT1197315).